Miglustat
The DOI matches its Crossref record; 19 of the 20 references it cites were found in a registry or an index.
Abstract
Miglustat is an orally administered ceramide glucosyltransferase inhibitor which prevents the lysosomal accumulation of glucocerebroside that occurs in patients with Gaucher's disease. In noncomparative trials in patients with type 1 Gaucher's disease, miglustat (50 or 100mg three times daily) for 6-12 months significantly reduced baseline liver and spleen volumes. At both 6 and 12 months, the reductions in organ volumes were greater with the higher dosage. Miglustat 50 or 100mg three times daily for 6-12 months had no significant effect on haemoglobin concentrations. Baseline platelet counts were not significantly improved by either dosage at 6 months, although the higher dosage significantly increased platelet counts at 12 months. In an open extension phase, patients continued to show further reductions in organ volume as well as significant improvements in haematological parameters at 24 and 36 months. black triangle In a 6-month randomised study in patients with type 1 Gaucher's disease who had previously received long-term enzyme replacement therapy (ERT), liver volume reduction was greater with miglustat plus ERT than with ERT alone. Diarrhoea and weight loss were the most frequent adverse events associated with miglustat therapy. Fine tremor has been reported in approximately 30% of miglustat-treated patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Miglustat inhibits the glucosylceramide synthase enzyme, which reduces biosynthesis of glucosylceramide from ceramide, resulting in reduced glycosphingolipids (GSLs) synthesis and deposition [235].”
From GANAB and N-Glycans Substrates Are Relevant in Human Physiology, Polycystic Pathology and Multiple Sclerosis: A Review (2022) · cites this paper as [235]
Citations
Cites
(2011) · Hepatogastroenterology · doi:10.5754/hge11069 · Cited by 1,140
Cox, T., Lachmann, R., Hollak, C., Aerts, J., van Weely, S., Hrebícek, M., Platt, F., Butters, T., Dwek, R., Moyses, C., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02161-9 · Cited by 744
N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis.
Platt, F. M., Neises, G. R., Dwek, R. A., & Butters, T. D. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37202-2 · Cited by 455
Jeyakumar, M., Butters, T. D., Cortina-Borja, M., Hunnam, V., Proia, R. L., Perry, V. H., Dwek, R. A., & Platt, F. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6388 · Cited by 267
Desforges, J. F., & Beutler, E. (1991) · New England Journal of Medicine · doi:10.1056/nejm199111073251906 · Cited by 252
Platt, F. M., Neises, G. R., Karlsson, G. B., Dwek, R. A., & Butters, T. D. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47132-3 · Cited by 175
Butters, T. D., van den Broek, L. A. G. M., Fleet, G. W. J., Krülle, T. M., Wormald, M. R., Dwek, R. A., & Platt, F. M. (2000) · Tetrahedron Asymmetry · doi:10.1016/s0957-4166(99)00468-1 · Cited by 147
Tsushima, H., Kawata, S., Tamura, S., Ito, N., Shirai, Y., Kiso, S., Doi, Y., Yamada, A., Oshikawa, O., & Matsuzawa, Y. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80001-4 · Cited by 118
Low-Dose N-Butyldeoxynojirimycin (OGT 918) for Type I Gaucher Disease
Heitner, R., Elstein, D., Aerts, J. M. F. G., van Weely, S., & Zimran, A. (2002) · Blood Cells Molecules and Diseases · doi:10.1006/bcmd.2002.0497 · Cited by 107
van der Spoel, A. C., Jeyakumar, M., Butters, T. D., Charlton, H. M., Moore, H. D. M., Dwek, R. A., & Platt, F. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.262586099 · Cited by 105
Research works printed but not linked: 1
- Beutler, 1993, Am J Dis Child, 147, 1175
Cited by
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Drugs, their targets and the nature and number of drug targets
Imming, P., Sinning, C., & Meyer, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2132 · Cited by 839
Natural products to drugs: natural product derived compounds in clinical trials
Butler, M. S. (2005) · Natural Product Reports · doi:10.1039/b402985m · Cited by 491
Carbohydrate-based drugs launched during 2000−2021
Cao, X., Du, X., Jiao, H., An, Q., Chen, R., Fang, P., Wang, J., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.020 · Cited by 267
Gaucher disease: a comprehensive review
Rosenbloom, B. E., & Weinreb, N. J. (2013) · Critical Reviews in Oncogenesis · doi:10.1615/critrevoncog.2013006060 · Cited by 181
Metadata
- Authors
- McCormack, P. L., & Goa, K. L.
- Corresponding author
- Goa, Karen L
- Venue
- Drugs
- Published
- 2003
- Volume
- 63
- Issue
- 22
- Pages
- 2427-2434
- ISSN
- 0012-6667 (ISSN-L)
- OpenAlex
- W3191861677
- Cited by
- 62
- References
- 20
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 6 · 2022: 5 · 2021: 3 · 2019: 2 · 2017: 3 · 2016: 1 · 2015: 1 · 2014: 3 · 2013: 6 · 2012: 2
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
- Keywords
- miglustat, Gaucher disease type 1, glucosylceramide, lysosomal accumulation, liver volume, spleen volume, hemoglobin, platelet count, enzyme replacement therapy, adverse events, tremor, diarrhea
- MeSH terms
- Clinical Trials as Topic, Gaucher Disease, Glucosylceramidase, Glucosyltransferases, Humans, Quality of Life
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Miglustat. https://app.cochat.ai/papers/10.2165/00003495-200363220-00006
- The paper
- McCormack, P. L., & Goa, K. L. (2003). Miglustat. Drugs. https://doi.org/10.2165/00003495-200363220-00006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.